Cite

Following its rapid adoption during COVID-19, there has been broad acceptance and recognition of the benefits of telemedicine in haemophilia care. Standardised guidelines on the virtual consultation process and how best to use clinical tools in a virtual setting could further transform practice.
Following its rapid adoption during COVID-19, there has been broad acceptance and recognition of the benefits of telemedicine in haemophilia care. Standardised guidelines on the virtual consultation process and how best to use clinical tools in a virtual setting could further transform practice.

Figure 1

Flow DiagramDiagram illustrating the flow of information through the different phases of the review process for identifying current literature available on telemedicine technology and the methods that facilitate direct-to-consumer delivery of clinical services for patients with haemophilia. The process follows that outlined in the PRISMA Statement 2009 [27].
Flow DiagramDiagram illustrating the flow of information through the different phases of the review process for identifying current literature available on telemedicine technology and the methods that facilitate direct-to-consumer delivery of clinical services for patients with haemophilia. The process follows that outlined in the PRISMA Statement 2009 [27].

j.jhp-2021-0011.tab.002

1 telemedicine/ (26865)
2 telemedic*.mp. (33375)
3 virtual.mp. (85819)
4 remote.mp. (92061)
5 online.mp. (196046)
6 telehealth/ (7593)
7 exp telecommunication/ (75872)
8 telehealth.mp. (11717)
9 telecommunic*.mp. (27328)
10 teleconsult*.mp. (10848)
11 mobile health*.mp. (5743)
12 mhealth.mp. (4757)
13 telemonitor*.mp. (4272)
14 video conferenc*.mp. (1448)
15 videoconferenc*.mp. (5623)
16 videoconferencing/ (4529)
17 virtual visit*.mp. (327)
18 telerehab*.mp. (1439)
19 telephone visit*.mp. (155)
20 hemophilia/ (19114)
21 Hemophili*.mp. (42023)
22 hemophilia A/ (21239)
23 hemophilia B/ (7944)
24 Haemophili*.mp. (14590)
25 Christmas diseas*.mp. (133)
26 Factor VIII deficienc*.mp. (639)
27 Factor IX deficienc*.mp. (357)
28 blood clotting factor 11 deficiency/ (1148)
29 Factor XI deficienc*.mp. (751)
30 Rosenthal syndrome.mp. (778)
31 royal disease.mp. (19)
32 blood clotting factor deficiency/ (923)
33 factor 8 deficienc*.mp. (26)
34 factor 9 deficienc*.mp. (6)
35 factor 11 deficienc*.mp. (1151)
36 factor 13 deficienc*.mp. (1037)
37 factor deficienc*.mp. (2807)
38 factor XIII deficienc*.mp. (760)
39 F VIII deficienc*.mp. (7)
40 FVIII deficienc*.mp. (363)
41 F IX deficienc*.mp. (3)
42 FIX deficienc*.mp. (182)
43 F XI deficienc*.mp. (19)
44 FXI deficienc*.mp. (467)
45 F XIII deficienc*.mp. (28)
46 FXIII deficienc*.mp. (540)
47 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (438724)
48 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 (47986)
49 47 and 48 (557)

j.jhp-2021-0011.tab.003

1 Telemedicine/ (24455)
2 telemedic*.mp. (30936)
3 virtual.mp. (62770)
4 Remote Consultation/ (4886)
5 remote.mp. (77587)
6 online.mp. (127647)
7 teleconsult*.mp. (1351)
8 telemonitor*.mp. (1671)
9 telehealth.mp. (5862)
10 mhealth.mp. (5076)
11 mobile health.mp. (8213)
12 video conferenc*.mp. (840)
13 videoconferenc*.mp. (3161)
14 virtual visit*.mp. (226)
15 exp Telecommunications/ (94549)
16 Telecommunic*.mp. (8668)
17 exp Telerehabilitation/ (413)
18 telerehab*.mp. (1064)
19 telephone visit*.mp. (84)
20 Hemophilia A/ (20710)
21 Hemophilia B/ (4384)
22 Hemophili*.mp. (26582)
23 Haemophili*.mp. (9660)
24 Christmas diseas*.mp. (330)
25 Factor VIII deficiency.mp. (413)
26 Factor IX deficiency.mp. (260)
27 Factor XI Deficiency/ (764)
28 Factor XI deficiency.mp. (864)
29 Rosenthal syndrome.mp. (917)
30 royal disease.mp. (20)
31 Factor XIII Deficiency/ (660)
32 factor XIII deficienc*.mp. (814)
33 factor 8 deficienc*.mp. (260)
34 factor 9 deficienc*.mp. (2)
35 factor 11 deficienc*.mp. (1)
36 factor 13 deficienc*.mp. (10)
37 factor deficienc*.mp. (1210)
38 FVIII deficienc*.mp. (151)
39 FIX deficienc*.mp. (72)
40 FXIII deficienc*.mp. (244)
41 FXI deficienc*.mp. (216)
42 F VIII deficienc*.mp. (5)
43 F IX deficienc*.mp. (1)
44 F XIII deficienc*.mp. (19)
45 F XI deficienc*.mp. (6)
46 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 (355256)
47 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 (31850)
48 46 and 47 (154)

Study characteristics

1 Jacobson K, Hooke C. Telehealth videoconferencing for children with hemophilia and their families: a clinical project. J PEDIATR ONCOL NURS 2016; 33(4): 282–8.
Month/year October 2015
Country USA
Study design Cross-sectional survey
Patient population (n) Severe haemophilia, ages 2–18 (n=12)
Healthcare team population & disciplines (n) HTC staff (n=4): healthcare providers, HTC nurse
Virtual medium Telephone, videoconferencing, email with photographs
Process of virtual consultation

Patient contacts clinic by phone to discuss bleeding with HTC nurse

Videoconferencing scheduled if HCP feels visualisation would be helpful

Documentation undertaken as a phone message

Outcomes Patients: Easy to access, easy to set up consultation with HCPs, felt that HCPs have a better understanding of bleed using video when compared to phone calls alone, 50% felt more confident caring for child after video conference.HCPs: 75% feel that same information could be achieved with phone call, 50% found telehealth visit to be better than phone call, 50% indifferent to video vs. phone call, 75% believe video consultations saved the need for patients to visit the hospital.
eISSN:
2055-3390
Idioma:
Inglés
Calendario de la edición:
Volume Open
Temas de la revista:
Medicine, Basic Medical Science, other, Clinical Medicine, Pharmacy, Pharmacology